Application of LRRC4 gene promoter zone methylation detection to glioma diagnosis and detection system

Abstract

The invention discloses an application of the LRRC4 gene promoter methylation detection to the glioma diagnosis and a detecting system thereof. The brain tissue specificity expressive gene LRRC4 is the glioma specificity methylate alienation gene, thereby indicating that the LRRC4 gene promoter methylation detection can be applied to the early period diagnosis of the glioma and the LRRC4 gene promoter methylation detecting system can be prepared by comprising a DNA bisulfite modification kit and an LRRC4 promoter methylation specificity PCR augmentation kit. The detecting system detects the specificity of the plasma LRRC4 promoter methylation state up to 92 percent, has high sensitivity, and can detect the plasma LRRC4 promoter methylation state of people quantificationally, thereby diagnosing the glioma of the patient rapidly without wound in the early time.

Description

technical field The invention relates to the application of hypermethylation of the promoter region of brain tissue-specific expression gene LRRC4 in the early diagnosis of glioma and the development of a methylation detection system for the promoter region of LRRC4 gene used for the early diagnosis of glioma. Background technique Statistics from the World Health Organization in 2007 showed that among nervous system tumors, glioma had the highest incidence rate, accounting for about 40.49%, and the peak age of onset was between 30-40 years old, or 10-20 years old, which seriously affected social productivity. For decades, although various improved treatment and diagnosis methods have been tried, including surgical treatment, chemotherapy, radiotherapy and imaging diagnostic techniques, etc., the survival time of malignant glioma has not been significantly improved. Therefore, screening and early diagnosis of high-risk groups for human glioma, so as to carry out early treatme...

AI Technical Summary

Problems solved by technology

At present, the reference standards for the diagnosis, staging and typing of glioma are based on clinical, pathological and imaging information, and are still in the stage of empirical standards, which are far from being able to adapt to human glioma. The need for screening and early diagnosis of high-risk groups

Due to the essential characteristics of "single gene multiple targets" of genetic tumor markers and the high heterogeneity at the cell level of solid tumors, the detection data of genetic (mutation, LOH and SNP) and expressive molecular markers are seriously interfered, The clinical application of biomarkers (heredity and expression) has great limitations

Images